Palliative Care Unit, Casa de Saúde da Idanha, Sintra, Portugal; Formerly Instituto Português de Oncologia de Lisboa, Lisbon, Portugal.
Department of Economics, Carleton University, Ottawa, Ontario, Canada.
J Pain Symptom Manage. 2018 Feb;55(2):297-306. doi: 10.1016/j.jpainsymman.2017.08.028. Epub 2017 Sep 21.
In patients with cancer pain, identifying a neuropathic pain component (NPC) may inform the selection of subsequent therapeutic interventions.
The objective of this study was to determine the prevalence, clinical characteristics, associated psychological distress, pre-referral treatment, and predictors of cancer pain with an NPC in patients referred to a cancer pain clinic.
Participants had standard assessments and documentation: Brief Pain Inventory ratings, presence of an NPC, based on a Douleur Neuropathique 4 (DN4) (neuropathic pain screening scale) score ≥4 combined with a physician's clinical assessment (blinded to DN4 result), the Hospital Anxiety Depression Scale, and Emotion Thermometer scores. Logistic regression analyses were used to determine predictors associated with an NPC.
Of 371 study participants, 120 (32.3%) had a designated NPC. Overall, psychological distress indices were similar in the NPC and nociceptive pain groups, except for a Hospital Anxiety and Depression Scale >7 score that was proportionately higher (74% vs. 63%, P = 0.03) in the nociceptive group. The final multivariable logistic regression model generated the following NPC predictors and their respective odds ratios (95% CIs): recent chemotherapy, 2.93 (1.63-5.26); recent surgery, 3.65 (2.03-6.59); adjuvant analgesic use, 2.93 (1.66-5.17); episodic incident pain, 2.63 (1.44-4.84); episodic breakthrough pain, 3.67 (2.00-6.73); pain duration three or more months, 2.35 (1.36-4.06); higher pain intensity, 1.47 (1.24-1.74); and pelvic or perineal pain location, 2.75 (1.09-6.96).
One in three patients with cancer have an NPC, which is independently associated with recent chemotherapy, surgery, adjuvant analgesic use, episodic incident and breakthrough pain, longer pain duration, higher pain intensity, and pelvic or perineal pain location.
在癌症疼痛患者中,确定神经性疼痛成分(NPC)可能有助于指导后续治疗干预措施的选择。
本研究的目的是确定在转诊至癌症疼痛诊所的患者中,NPC 癌症疼痛的患病率、临床特征、相关心理困扰、转诊前治疗以及预测因素。
参与者接受了标准评估和记录:简要疼痛量表评分、NPC 的存在,基于 Douleur Neuropathique 4(DN4)(神经性疼痛筛查量表)评分≥4 分,结合医生的临床评估(对 DN4 结果进行盲法)、医院焦虑抑郁量表和情绪温度计评分。使用逻辑回归分析确定与 NPC 相关的预测因素。
在 371 名研究参与者中,120 名(32.3%)有指定的 NPC。总体而言,NPC 组和伤害感受性疼痛组的心理困扰指数相似,除了医院焦虑和抑郁量表评分>7 的比例较高(74%比 63%,P=0.03),NPC 组比例较高。最终的多变量逻辑回归模型生成了以下 NPC 预测因素及其各自的比值比(95%置信区间):近期化疗,2.93(1.63-5.26);近期手术,3.65(2.03-6.59);辅助镇痛药物使用,2.93(1.66-5.17);阵发性事件性疼痛,2.63(1.44-4.84);阵发性爆发性疼痛,3.67(2.00-6.73);疼痛持续时间三个月或更长时间,2.35(1.36-4.06);更高的疼痛强度,1.47(1.24-1.74);以及盆腔或会阴疼痛部位,2.75(1.09-6.96)。
三分之一的癌症患者有 NPC,其与近期化疗、手术、辅助镇痛药物使用、阵发性事件性和爆发性疼痛、更长的疼痛持续时间、更高的疼痛强度以及盆腔或会阴疼痛部位独立相关。